A431 Transfection Reagent (Epidermoid Carcinoma)

$285.00$1,609.00

Kit Size VolumePriceAdd to Cart
0.5 ml (Catalog #1170)$285.00
1.5 ml (Catalog #1171)$603.00
1.5 ml CRISPR (Catalog #2103)$803.00
8.0 ml (Catalog #7020)$1,609.00
SKU: A431TR Category:

Description

Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).

Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).


Transfection Reagent for A431 Cells (Epidermoid Carcinoma Cells, CRL-1555)

  • Proprietary cationic lipids formulation
  • High transfection efficiency of small RNA (siRNA, shRNA, miRNA), mRNA, pDNA
  • Effective and robust intracellular delivery
  • Kit includes Transfection Enhancer reagent
  • Produces consistent results, lot-to-lot, plate-to-plate, and well-to-well
  • Work in the presence of serum
  • A proven reagent for establishing stable cell lines
  • Optimized transfection protocols are adapted for use with both standard & reverse transfection methods
  • Download in vitro A431 transfection protocol: [PDF]
  • Download A431 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for A431 cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089713
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 81% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.

Transfection Protocol and MSDS:

Download Altogen Biosystems A431 Transfection Protocol: [PDF]

Download MSDS: [PDF]

A-431 Cell Line:

According to the American Cancer Society, epidermoid or squamous cell carcinoma is one of the most prevalent types of skin cancer that occurs in various parts of the body, with over 1 million cases being diagnosed annually. It can be triggered by UV exposure, and new therapies for advanced stages of the disease are desperately needed. There are over thirty cancer cell lines that are used in epidermoid and squamous cell carcinoma research including A-431. The A-431 cell line was established from the epidermis (skin) of an 85-year-old female patient who suffered from epidermoid carcinoma. These cells exhibit an epithelial morphology and are tumorigenic. A-431 was derived by D.J. Giard et al. from solid tumors, along with many other cell lines. This cell line could be useful for studying of medical treatments and for research of certain types of skin cancer.

Mutations:

TP53 7157 37 17 7577120 7577120 Missense_Mutation SNP C T
KHDRBS2 202559 37 6 62995783 62995783 Missense_Mutation SNP G A
LINGO2 158038 37 9 27949442 27949442 Missense_Mutation SNP G T
ZNF488 118738 37 10 48370999 48370999 Missense_Mutation SNP G A
PDE3A 5139 37 12 20766419 20766419 Missense_Mutation SNP G A
DAAM1 23002 37 14 59834206 59834206 Missense_Mutation SNP C G
HK3 3101 37 5 176314737 176314737 Missense_Mutation SNP C T
OR5B2 390190 37 11 58189810 58189810 Missense_Mutation SNP G C
ZFC3H1 196441 37 12 72057069 72057069 Missense_Mutation SNP C G
CDAN1 146059 37 15 43017747 43017747 Silent SNP C T

Data:

A431 Cell Transfection Reagent

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into A431 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

A431-cells-transfection-protocol

Figure 2. Protein expression of Lamin A/C in A431 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into A431 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
  • Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF]
  • Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Biosystems:

Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and preoptimized transfection kits, elecroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.

Altogen Labs Research Services:

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml (Catalog #1170)
  • 1.5 ml (Catalog #1171)
  • 1.5 ml CRISPR (Catalog #2103)
  • 8.0 ml (Catalog #7020)

Additional information

Weight 1 lbs
Kit Size (Volume)

0.5 ml (Catalog #1170), 1.5 ml (Catalog #1171), 1.5 ml CRISPR (Catalog #2103), 8.0 ml (Catalog #7020)